

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**


Claim 1 (currently amended): A compound ~~comprising having the structure shown in~~

Formula 1:

R-L-S

(I)

wherein ~~R is a fluorescent dye molecule an acridone dye of Formula II:~~



(II)

wherein:

groups R<sup>2</sup> and R<sup>3</sup> are attached to the Z<sup>1</sup> ring structure and groups R<sup>4</sup> and R<sup>5</sup> are attached to the Z<sup>2</sup> ring structure;


Z<sup>1</sup> and Z<sup>2</sup> independently represent the atoms necessary to complete one or two fused ring

aromatic or heteroaromatic systems, each ring having five or six atoms selected from carbon atoms and optionally no more than two atoms selected from oxygen, nitrogen and sulphur;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are independently selected from hydrogen, halogen, amide, hydroxyl, cyano, amino, mono- or di-C<sub>1</sub>-C<sub>3</sub> alkyl-substituted amino, sulphhydryl, carbonyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, aryl, heteroaryl, C<sub>1</sub>-C<sub>20</sub> alkyl, aralkyl; the group -E-F where E is a spacer group having a chain from 1-60 atoms selected from the group consisting of carbon, nitrogen, oxygen, sulphur and phosphorus atoms and F is a target bonding group; and the group -(CH<sub>2</sub>)<sub>n</sub>Y where Y is selected from sulphonate, sulphate, phosphonate, phosphate, quaternary ammonium and carboxyl and n is zero or an integer from 1 to 6;

L is an optional linkage group containing ~~from 2 to 30 one or more~~ atoms comprising hydrocarbon chains which may also contain other atoms such as N, O and S; and

S is ~~molecule comprising~~ a substrate group of the enzyme aromatase of formula IX



(IX)

wherein:

R<sup>1'</sup> and R<sup>2'</sup> are selected from H and methyl;

R<sup>3'</sup> is selected from H, C<sub>1</sub>-C<sub>8</sub> alkyl, cyano, -(CH<sub>2</sub>)<sub>k</sub>-OR<sup>a</sup>;

-(CH<sub>2</sub>)<sub>k</sub>-COOR<sup>a</sup>; -(CH<sub>2</sub>)<sub>k</sub>-SO<sub>2</sub>R<sup>a</sup>; -(CH<sub>2</sub>)<sub>k</sub>-CHO, -(CH<sub>2</sub>)<sub>k</sub>-NR<sup>b</sup>R<sup>c</sup> and

-(CH<sub>2</sub>)<sub>k</sub>-COR<sup>d</sup>;

R<sup>4'</sup> is selected from H, -COR<sup>a</sup> and hydroxyl;

R<sup>5'</sup> is selected from H, -COR<sup>a</sup>, hydroxyl, cyano and halide;

R<sup>6'</sup> is selected from H and hydroxyl;

R<sup>7'</sup>, R<sup>8'</sup> and R<sup>9'</sup> are independently selected from H, -COR<sup>a</sup> and hydroxyl;

R<sup>10'</sup> is selected from H and halide; and

where R<sup>a</sup> is selected from H and C<sub>1</sub>-C<sub>4</sub> alkyl, optionally substituted with OH; R<sup>b</sup> and R<sup>c</sup>

are selected from H and C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>d</sup> is selected from C<sub>1</sub>-C<sub>8</sub> alkyl or C<sub>1</sub>-C<sub>8</sub> alkyl optionally substituted with COOR<sup>a</sup>, OH,

OR<sup>a</sup> or SO<sub>2</sub>R<sup>a</sup>;


and k is zero or an integer from 1 to 8;

and further wherein the fluorescence signal of said compound changes in respect of  
fluorescence lifetime when the compound is acted upon in vitro or in vivo by an enzyme  
with aromatase activity.

Claims 2-5 (cancelled)

Claim 6 (previously presented): The compound of claim 1, wherein L is a linker group  
containing from 6 to 20 atoms.

Claim 7 (previously presented): The compound of claim 1, wherein L is a linker group selected from the group:



where each Q is selected from CHR', NR', O, -CH=CH-, Ar and -CONH-;

each R' is independently hydrogen or C<sub>1</sub> to C<sub>4</sub> alkyl;

each p is independently 0 to 5;

each r is independently 0 to 5;

and s is either 1 or 2.


Claim 8 (previously presented): The compound of claim 7, wherein Q is selected from the group consisting of -CHR'-, -O- and -CONH-, where R' is hydrogen or C<sub>1</sub> to C<sub>4</sub> alkyl.

Claim 9 (cancelled)

Claim 10 (currently amended): The compound of claim 1-~~claim 9~~, wherein Group S is a steroid selected from the group of steroid families consisting of 4-androsten-3-one, 4-cholesten-3-one, 4-estren-3-one and 4-pregnen-3-one derivatives.

Claims 11-12 (cancelled)

Claim 13 (previously presented): The compound of claim 1, having Formula XX



Claim 14 (previously presented): A method for measuring aromatase activity in a sample, the method comprising the steps of:

- i) measuring the fluorescence lifetime of the compound of claim 1 prior to adding it to said sample;
- ii) adding said compound to said sample under conditions which favour aromatase activity, and
- iii) measuring a change in fluorescence lifetime of said compound following step ii);

wherein said change in fluorescence lifetime can be used to determine aromatase activity.

Claim 15 (previously presented): The method of claim 14, wherein the sample is selected from the group consisting of extract, cell, tissue and organism.

Claim 16 (previously presented): A method of screening for a test agent whose effect upon the activity of aromatase is to be determined, said method comprising the steps of:

- i) performing the method of claim 14 in the presence of said agent; and
- ii) comparing the activity of said aromatase in the presence of the agent with a known value for the activity of aromatase in the absence of the agent;

wherein a difference between the activity of the aromatase in the presence of the agent and said known value in the absence of the agent is indicative of the effect of the test agent upon the activity of aromatase.

Claim 17 (previously presented): The method of claim 16, wherein the known value is stored in an electronic database.

Claim 18 (previously presented): A method of screening for a test agent whose effect upon the activity of aromatase is to be determined, said method comprising the steps of:

- i) performing the method of claim 16 in the presence and in the absence of the agent; and
- ii) determining the activity of said enzyme in the presence and in the absence of the agent;

wherein a difference between the activity of aromatase in the presence and in the absence of the agent is indicative of the effect of the test agent upon the activity of aromatase.

Claim 19 (previously presented): The method of claim 17, wherein said difference in

activity between the activity of aromatase in the absence and in the presence of the agent is normalised, stored electronically and compared with a value of a reference compound.

Claim 20 (previously presented): A method for measuring the distribution of the compound of claim 1 within a tissue, wherein the compound is capable of being taken up by a living cell within said tissue, the method comprising the steps of:

- i) measuring the fluorescence lifetime of the compound in a cell-free environment or a parental host cell;
- ii) adding the compound to one or more cells or a cell engineered to over-express aromatase, and
- iii) measuring the fluorescence lifetime of the compound following step ii);

wherein a change in fluorescence lifetime indicates aromatase activity and can be used to determine the distribution of the compound.

Claim 21 (previously presented): The method of claim 20, wherein the distribution of the compound within the tissue of a first subject is compared with the distribution of the compound within the tissue of a second subject.

Claim 22 (original): The method of claim 21, wherein said subject is selected from the group consisting of mammal, plant, insect, fish, bird, fly, nematode and algae.

Claim 23 (original): The method of claim 22, wherein the mammal is a mouse or a rat.

Claim 24 (cancelled)

Claim 25 (previously presented): In a method of diagnosing a disease caused by an increase in aromatase activity in a subject, the improvement comprising performing the method of claim 14, and comparing the activity of aromatase in a sample taken from the subject with the activity in a sample taken from a second healthy control subject, wherein any increase in activity measured in the sample taken from the subject relative to the second healthy control subject is indicative of disease.

Claim 26 (previously presented): A kit comprising:

- i) the compound of claim 1; and
- ii) an assay buffer.